ANXA2
ATC code L01
AbbVie
Abemaciclib
Acalabrutinib
Acrylamide
Adagrasib
Adipotide
Afatinib
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Antineoplastic
Apoptosis
Arthralgia
Asciminib
Atezolizumab
Atezolizumab/hyaluronidase
Atrial fibrillation
Aumolertinib
Avapritinib
Avelumab
Axatilimab
Axitinib
B-cell activating factor
B-cell receptor
BRAF (gene)
B cell
Baricitinib
Basal-cell carcinoma
Bcr-abl fusion protein
Belantamab mafodotin
Bermekimab
Bevacizumab
Binimetinib
Biological half-life
Blinatumomab
Bosutinib
Brentuximab vedotin
Brigatinib
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CXCL12
CXCL13
CXCR4
CYP2D6
CYP3A
Cabozantinib
Cancer immunotherapy
Capmatinib
Catumaxomab
Cediranib
Celera Genomics
Cemiplimab
Ceritinib
Cetuximab
ChEBI
ChEMBL
ChemSpider
Chemical formula
Chemokine
Chemotaxis
Chronic lymphocytic leukemia
Cobimetinib
CompTox Chemicals Dashboard
Copanlisib
Cosibelimab
Crizotinib
Dabrafenib
Dacomitinib
DailyMed
Dalpiciclib
Daratumumab
Dasatinib
Denileukin diftitox
Dinutuximab beta
Dizziness
Doi (identifier)
Dostarlimab
DrugBank
Drug metabolism
Drug nomenclature
Drugs.com
Durvalumab
Duvelisib
ECHA InfoCard
EML4
Edema
Edrecolomab
Elotuzumab
Elranatamab
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
ErbB
Erdafitinib
Erlotinib
European Medicines Agency
Everolimus
Excretion
Exotoxin
Extracellular signal-regulated kinases
Fedratinib
Fibroblast growth factor receptor
Fibronectin
Filgotinib
Food and Drug Administration
Fruquintinib
Fusion protein
Futibatinib
Gefitinib
Gemtuzumab ozogamicin
Gilteritinib
Glasdegib
Glofitamab
Graft-versus-host disease
Grapefruit juice
Guide to Pharmacology
HER2/neu
Hdl (identifier)
Hedgehog signaling pathway
Hives
Hypertension
Hyperuricemia
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib (data page)
Icotinib
Idelalisib
Imatinib
Inavolisib
Indicated
Infigratinib
Inflation Reduction Act
Inotuzumab ozogamicin
Interleukin 2
Interleukin 4
Interleukin 6
International Chemical Identifier
Interstitial lung disease
Ipilimumab
Isatuximab
JSmol
Janssen Pharmaceutica
Janus kinase
Johnson & Johnson
KEGG
KRAS
Lapatinib
Larotrectinib
Lazertinib
Lenvatinib
Lestaurtinib
Leukemia
Leukopenia
Loncastuximab tesirine
Lorlatinib
Lymphadenopathy
Lymphatic system
Lymphocytopenia
Lymphocytosis
Lymphoma
MCL1
MEN1
MTOR inhibitor
Mantle cell lymphoma
Masitinib
Medicare (United States)
MedlinePlus
Midostaurin
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibody therapy
Mosunetuzumab
Moxetumomab pasudotox
Myeloid
NF-κB
National Cancer Institute
Naxitamab
Necitumumab
Neratinib
Neutropenia
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Odronextamab
Ofatumumab
Olaratumab
Olmutinib
Oportuzumab monatox
Oral administration
Orelabrutinib
Osimertinib
PI3K/AKT/mTOR pathway
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pazopanib
Pembrolizumab
Pemigatinib
Pertuzumab
Petechia
Pexidartinib
Pharmacokinetics
Pharmacyclics
Pi3K inhibitor
Pirtobrutinib
Plasma protein binding
Platelet-derived growth factor receptor
Pneumonia
Polatuzumab vedotin
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Proapoptotic
Prohibitin
Prolgolimab
Protein Data Bank
PubChem
Public domain
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Reagent
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Repotrectinib
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Ripretinib
Rituximab
Rociletinib
Route of administration
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Selpercatinib
Selumetinib
Semaxanib
Sepsis
Serplulimab
Simplified molecular-input line-entry system
Sinusitis
Sirolimus
Small molecule
Sonidegib
Sorafenib
Sotorasib
Squamous cell carcinoma
Src (gene)
Standard for the Uniform Scheduling of Medicines and Poisons
Stomatitis
Subdural hematoma
Sugemalimab
Sunitinib
TNF-α
Tafasitamab
Talquetamab
Targeted cancer therapy
Targeted covalent inhibitor
Tarlatamab
Tebentafusp
Teclistamab
Temsirolimus
Tepotinib
The Wall Street Journal
The Washington Post
Thrombocytopenia
Tislelizumab
Tisotumab vedotin
Tivozanib
Toceranib
Toripalimab
Tositumomab
Trametinib
Trastuzumab
Trastuzumab/hyaluronidase
Trastuzumab deruxtecan
Trastuzumab emtansine
Tremelimumab
Trilaciclib
Tucatinib
Tumor lysis syndrome
Tyrosine kinase inhibitor
Unique Ingredient Identifier
Upper respiratory tract infection
Urinary tract infection
VEGF receptors
Vandetanib
Vascular endothelial growth factor
Vascular endothelial growth factor A
Vemurafenib
Venetoclax
Vismodegib
WHO Model List of Essential Medicines
Waldenström's macroglobulinemia
World Health Organization
Zanidatamab
Zanubrutinib
Zenocutuzumab
Zolbetuximab